CTCFL and glioblastoma: The present study confirms that a large proportion of glioblastomas present CTA expression, suggesting that ACTL8, CTCFL, OIP5 and XAGE3 may be eligible for future vaccines clinical trials targeting multiple antigens; however, the demonstration of immunogenicity in the human host is crucial for these CTA be considered as a potential cancer vaccine target.